Newbury Pharmaceuticals

Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Buspirone tablets.

“Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters). With the addition of Buspirone we have also secured a new strategic partnership which can be used to source additional new products.” says Mr Lars Minor CEO of Newbury

Regulatory filling will take place in the near time, and we aim to launch this medicine in Sweden and Finland where the total annual value of the market is estimated to be 1,5 MEUR according to DLMI Nordic Pharma Insights.

Newbury currently has more than 30 products in its portfolio and the first launches took place in 2022 with additional launches planned in the years ahead.

Datum 2023-02-02, kl 07:45
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.